Lupin has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Nagpur facility. The facility was inspected by the USFDA between August 5, 2019 and August 8, 2019. The inspection for the oral solid facility at Nagpur closed without any Form 483 observation. The Nagpur facility is company’s largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
